IVVD
Biotechnology · Healthcare
Chairman, CEO, Board Member
2022-07-01–present
Equibles does not estimate personal net worth.
Marc Elia is recorded as Analyst at Chairperson of the Board, CEO at Invivyd, Inc. (IVVD) since August 30, 2026, Board Member at Invivyd, Inc. (IVVD) since July 1, 2022 and Chairman at Invivyd, Inc. (IVVD). Invivyd, Inc. reported in an 8-K filed September 1, 2026 that Marc Elia was appointed Chief Executive Officer (CEO), effective September 1, 2026. Invivyd, Inc. reported in an 8-K filed September 1, 2026 that Marc Elia was appointed Chief Executive Officer, effective August 30, 2026. Invivyd, Inc. reported in an 8-K filed July 5, 2022 that Marc Elia was appointed Chair of the Board of Directors, effective July 1, 2022. Equibles holds 4 filed executive changes naming Marc Elia; each is listed under recent activity with its source filing. Marc Elia has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Invivyd, Inc. on November 6, 2025. Invivyd, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Invivyd, Inc. includes Jeremy Gowler (CEO and COO), William Duke, Jr. (CEO), Frederick W. Driscoll (CFO) and 7 others.
“Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as Chief Executive Officer (CEO) of the company.”
“On August 30, 2026, the Board of Directors (the "Board") of Invivyd, Inc. (the "Company") appointed Marc Elia, Chairman of the Board, as the Company's Chief Executive Officer, effective as of August 30, 2026 (the "Effective Date").”
“The third quarter for Invivyd marked a turning point in our company's history, and we hope also mark the beginning of substantial change in how we may prevent COVID for vulnerable Americans in the near future.”
“Good morning, and thank you all for joining our Revolution Clinical Program update call this morning. We understand that this morning is busy with earnings calls, and so a replay of our call will, of course, be available shortly after we conclude.”
“Turning to Slide 4, the first quarter and our early second quarter has been a very busy and productive time marked by transition.”
“The third quarter at Invivyd was marked by a promising start and then an unusual commercial headwind that Invivyd has been managing since.”
2026-08-30–present
2022-07-01–present
Chairperson of the Board
Analyst
Source not stated
IVVD
Biotechnology · Healthcare
Chairman, CEO, Board Member
2022-07-01–present